Oddo Bhf Analysts Give MorphoSys (ETR:MOR) a €110.00 Price Target
Other research analysts also recently issued reports about the company. Independent Research set a €103.00 ($119.77) price target on MorphoSys and gave the company a buy rating in a report on Tuesday, May 8th. Goldman Sachs Group set a €86.00 ($100.00) target price on MorphoSys and gave the stock a neutral rating in a research note on Thursday, May 3rd. Royal Bank of Canada set a €62.00 ($72.09) target price on MorphoSys and gave the stock a sell rating in a research note on Wednesday, June 13th. Berenberg Bank set a €103.00 ($119.77) target price on MorphoSys and gave the stock a buy rating in a research note on Tuesday, May 15th. Finally, Bryan, Garnier & Co set a €91.00 ($105.81) target price on MorphoSys and gave the stock a buy rating in a research note on Monday, April 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of €95.40 ($110.93).
Shares of MorphoSys traded down €1.40 ($1.63), reaching €105.60 ($122.79), on Thursday, MarketBeat Ratings reports. 82,856 shares of the stock were exchanged, compared to its average volume of 153,687. MorphoSys has a twelve month low of €49.63 ($57.71) and a twelve month high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.